Resource Center
Abstracts
-
Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose.
DeFronzo RA, Abdul-Ghani M. Am J Cardiol. 2011;108(3 Suppl):3B-24B.
-
Fasting Might Not Be Necessary Before Lipid Screening: A Nationally Representative Cross-sectional Study.
Steiner MJ, Skinner AC, Perrin EM. Pediatrics. 2011. [Epub ahead of print]
-
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Barter PJ, Rye KA, Tardif JC, et al. Circulation. 2011;124:555-562.
-
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
Stalenhoef AF, Davidson MH, Robinson JG, et al. Diabetes Obes Metab. 2011. [Epub ahead of print]
-
Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial.
Jenkins DJ, Jones PJ, Lamarche B, et al. JAMA. 2011;306:831-839.
-
Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis.
Buitrago-Lopez A, Sanderson J, Johnson L, et al. BMJ. 2011;343:d4488
-
Impact of diabetes mellitus on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) educational program.
Tocci G, Ferrucci A, Guida Pet al. Clin Cardiol. 2011;34:560-566.
-
Obesity phenotype and cardiovascular changes.
Park J, Kim SH, Cho GY, et al. J Hypertens. 2011;29:1765-1772.
-
Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals.
Voulgari C, Tentolouris N, Dilaveris P, et al. J Am Coll Cardiol. 2011;58:1343-1350.
-
Fenofibrate: a review of its use in dyslipidaemia.
McKeage K, Keating GM. Drugs. 2011;71:1917-1946.
-
Serum triglycerides and risk of cardiovascular disease.
Boullart AC, de Graaf J, Stalenhoef AF. Biochim Biophys Acta. 2011. [Epub ahead of print]
-
Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol.
Lee KH, Jeong MH, Kim HM, et al. J Am Coll Cardiol. 2011;58:1664-1671.
-
Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: the multi-ethnic study of atherosclerosis.
Malik S, Budoff MJ, Katz R, et al. Diabetes Care. 2011;34:2285-2290.
-
Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome: A Post Hoc ATTEMPT Analysis.
Athyros VG, Elisaf MS, Alexandrides T, et al. Angiology. 2011. [Epub ahead of print]
-
Cardiovascular Risk Prediction in Diabetic Men and Women Using Hemoglobin A1c vs Diabetes as a High-Risk Equivalent.
Paynter NP, Mazer NA, Pradhan AD, et al. Arch Intern Med. 2011;171:1712-1718.
-
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Fayad ZA, Mani V, Woodward M, et al. Lancet. 2011;378:1547-1559.
-
Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study.
Banegas JR, López-García E, Dallongeville J, et al. Int J Cardiol. 2011. [Epub ahead of print]
-
Effect of bariatric surgery on cardiovascular risk profile.
Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Am J Cardiol. 2011;108:1499-1507.
-
Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors.
Wannamethee SG, Shaper AG, Whincup PH, et al. Arch Intern Med. 2011;171:404-410.
-
Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
Hsia J, MacFadyen JG, Monyak J, et al. J Am Coll Cardiol. 2011;57:1666-1675.
-
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Schramm TK, Gislason GH, Vaag A, et al. Eur Heart J. 2011. [Epub ahead of print]
-
Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.
Waters DD, Ho JE, DeMicco DA, et al. J Am Coll Cardiol. 2011;57:1535-1545.
-
Adolescent BMI trajectory and risk of diabetes versus coronary disease.
Tirosh A, Shai I, Afek A, et al. N Engl J Med. 2011;364:1315-325.
-
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM, Allison DB, Ryan DH, et al. Lancet. 2011;377:1341-1352. Erratum in: Lancet. 2011;377:1494.
-
The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.
West AM, Anderson JD, Meyer CH, et al. Atherosclerosis. 2011. [Epub ahead of print]
-
Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data.
Coutinho T, Goel K, Corręa de Sá D, et al. J Am Coll Cardiol. 2011;57:1877-1886.
-
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Goldberg AC, Hopkins PN, Toth PP, et al. J Clin Lipidol. 2011;5:133-140.
-
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.
Piccinni C, Motola D, Marchesini G, et al. Diabetes Care. 2011;34:1369-1371.
-
Metabolic Syndrome, Cardiovascular Disease, and Risk for Chronic Kidney Disease in an Italian Cohort: Analysis of the INCIPE Study.
Ferraro PM, Lupo A, Yabarek T, et al. Metab Syndr Relat Disord. 2011. [Epub ahead of print]
-
Glycation of LDL by Methylglyoxal Increases Arterial Atherogenicity: A Possible Contributor to Increased Risk of Cardiovascular Disease in Diabetes.
Rabbani N, Godfrey L, Xue M, et al. Diabetes. 2011;60:1973-1980.
-
Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality.
Hill J, Heslop C, Man SF, et al. Eur Heart J. 2011. [Epub ahead of print]
-
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
Preiss D, Seshasai SR, Welsh P, et al. JAMA. 2011;305:2556-2564.
-
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2•7 million participants.
Danaei G, Finucane MM, Lu Y, et al. Lancet. 2011;378:31-40.
-
Predictors of Coronary Heart Disease Events Among Asymptomatic Persons With Low Low-Density Lipoprotein Cholesterol MESA (Multi-Ethnic Study of Atherosclerosis).
Blankstein R, Budoff MJ, Shaw LJ, et al. J Am Coll Cardiol. 2011;58:364-374.
-
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM. Am J Cardiovasc Drugs. 2011;11:227-247.
-
Kidney disease in cardiology.
Herzog CA. Nephrol Dial Transplant. 2011;26:46-50
-
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).
Herzog CA, Asinger RW, Berger AK, et al. Kidney Int. 2011. [Epub ahead of print]
-
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Sharp Collaborative Group. Am Heart J. 2010;160:785-794.e10.
-
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy.
Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Casciola-Rosen LA. Arthritis Rheum. 2010 Nov 19. [Epub ahead of print]
-
Diets with high or low protein content and glycemic index for weight-loss maintenance.
Larsen TM, Dalskov SM, van Baak M, et al; Diet, Obesity, and Genes (Diogenes) Project. N Engl J Med. 2010;363:2102-2113.
-
Body-mass index and mortality among 1.46 million white adults.
Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. N Engl J Med. 2010;363:2211-2219.
-
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.
Athyros VG, Tziomalos K, Gossios TD, et al; GREACE Study Collaborative Group. Lancet. 2010;376:1916-1922.
-
Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk.
Jafri H, Alsheikh-Ali AA, Karas RH. Ann Intern Med. 2010;153:800-808.
-
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.
Khera AV, Cuchel M, de la Llera-Moya M, et al. N Engl J Med. 2011;364:127-135.
-
Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
Nicholls SJ, Tuzcu EM, Wolski K, et al. J Am Coll Cardiol. 2011;57:153-159.
-
Multiple risk factor interventions for primary prevention of coronary heart disease.
Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD001561. Review.
-
Statins for the primary prevention of cardiovascular disease.
Taylor F, Ward K, Moore TH, et al. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. Review.
-
Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective.
Elam M, Lovato LC, Ginsberg H. Curr Opin Lipidol. 2011;22:55-61.
-
Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register.
Eriksson M, Zethelius B, Eeg-Olofsson K, et al. Eur J Cardiovasc Prev Rehabil. 2011;18:97-105.
-
Physical Activity Modifies the Effect of LPL, LIPC, and CETP Polymorphisms on HDL-C Levels and the Risk of Myocardial Infarction in Women of European Ancestry.
Ahmad T, Chasman DI, Buring JE, Lee IM, Ridker PM, Everett BM. Circ Cardiovasc Genet. 2011;4:74-80.
-
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study.
Heart Protection Study Collaborative Group, Jonathan Emberson, Derrick Bennett, et al. Lancet. 2011;377:469-476.
-
Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study.
Owan T, Avelar E, Morley K, et al. J Am Coll Cardiol. 2011;57:732-739.
-
Metabolic syndrome and cognitive decline in French elders: the Three-City Study.
Raffaitin C, Féart C, Le Goff M, et al. Neurology. 2011;76:518-525.
-
The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels.
Choudhry NK, Patrick AR, Glynn RJ, Avorn J. J Am Coll Cardiol. 2011;57:784-791.
-
Vasomotor symptoms and cardiovascular events in postmenopausal women.
Szmuilowicz ED, Manson JE, Rossouw JE, et al. Menopause. 2011 Feb 19. [Epub ahead of print]
-
Association between body-mass index and risk of death in more than 1 million Asians.
Zheng W, McLerran DF, Rolland B, et al. N Engl J Med. 2011;364:719-729.
-
Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.
Mellbin LG, Malmberg K, Norhammar A, Wedel H, Rydén L; for the DIGAMI 2 Investigators. Diabetologia. 2011 Feb 26. [Epub ahead of print]
-
Cardiovascular disease in recent onset diabetes mellitus.
Yamagishi SI. J Am Coll Cardiol. 2011 Feb 28. [Epub ahead of print]
-
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial.
The AIM-HIGH Investigators. Am Heart J. 2011;161:538-543.
-
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Nicholls SJ, Gordon A, Johansson J, et al. J Am Coll Cardiol. 2011;57:1111-1119.
-
Long-term effects of intensive glucose lowering on cardiovascular outcomes.
ACCORD Study Group. N Engl J Med. 2011;364:818-828.
-
A Better Index of Body Adiposity.
Bergman RN, Stefanovski D, Buchanan TA, et al. Obesity. 2011 Mar 3. [Epub ahead of print]
-
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies.
The Emerging Risk Factors Collaboration. Lancet. 2011 Mar 10. [Epub ahead of print]
-
Prevalence of the metabolic syndrome as influenced by the measure of obesity employed
Vega GL, Barlow CE, Grundy SM. Am J Cardiol. 2010;105:1306-1312.
-
Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries
Mente A, Yusuf S, Islam S, et al. J Am Coll Cardiol. 2010;55:2390-2398.
-
PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses
Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. J Am Coll Cardiol. 2010;55:2833-2842.
-
Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy
Jafri H, Alsheikh-Ali AA, Karas RH. J Am Coll Cardiol. 2010;55:2846-2854.
-
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Lancet. 2010;375:2215-2222.
-
Diabetes mellitus, glycemic control, and risk of atrial fibrillation
Dublin S, Glazer NL, Smith NL, et al. J Gen Intern Med. 2010;25:853-858.
-
Effect of nateglinide on the incidence of diabetes and cardiovascular events
NAVIGATOR Study Group, Holman RR, Haffner SM, et al. N Engl J Med. 2010;362:1463-1476.
-
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Pratley RE, Nauck M, Bailey T, et al. Lancet. 2010;375:1447-1456.
-
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial
Riddle MC, Ambrosius WT, Brillon DJ, et al. Diabetes Care. 2010;33:983-990.
-
Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies
Ziemer DC, Kolm P, Weintraub WS, et al. Ann Intern Med. 2010;152:770-777.
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Bergenstal RM, Wysham C, Macconell L, et al. Lancet. 2010 Jun 25. [Epub ahead of print].
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Diamant M, Van Gaal L, Stranks S, et al. Lancet. 2010;375:2234-2243.
-
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
Zinman B, Harris SB, Neuman J, et al. Lancet. 2010;376:103-111.
-
Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia
Ladenson PW, Kristensen JD, Ridgway EC, et al. N Engl J Med. 2010;362:906-916.
-
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial
Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Ann Intern Med. 2010;152:488-496, W174.
-
Caloric sweetener consumption and dyslipidemia among US adults
Welsh JA, Sharma A, Abramson JL, Vaccarino V, Gillespie C, Vos MB. JAMA. 2010;303:1490-1497.
-
Effects of combination lipid therapy in type 2 diabetes mellitus
ACCORD Study Group, Ginsberg HN, Elam MB, et al. N Engl J Med. 2010;362:1563-1574.
-
Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials
Sabaté J, Oda K, Ros E. Arch Intern Med. 2010;170:821-827.
-
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration
Villines TC, Stanek EJ, Devine PJ, et al. J Am Coll Cardiol. 2010;55:2721-2726.
-
A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome
Waksman R, Torguson R, Kent KM, et al. J Am Coll Cardiol. 2010;55:2727-2735.
-
Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal
de Lorgeril M, Salen P, Abramson J, et al. Arch Intern Med. 2010;170:1032-1036.
-
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants
Ray KK, Seshasai SR, Erqou S, et al. Arch Intern Med. 2010;170:1024-1031.
-
Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)
Ridker PM, MacFadyen J, Libby P, Glynn RJ. Am J Cardiol. 2010;106:204-209.
-
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study
Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH. Am J Cardiovasc Drugs. 2008;8:69-81.
-
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation
Brunzell JD, Davidson M, Furberg CD, et al. J Am Coll Cardiol. 2008;51:1512-1524.
-
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
Nissen SE, Nicholls SJ, Wolski K, et al.; STRADIVARIUS Investigators. JAMA. 2008;299:1547-1560.
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. N Engl J Med. 2006;355:2427-2443. Erratum in: N Engl J Med. 2007;356:1387-1388.
-
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. JAMA. 2006;295:761-775. Erratum in: JAMA. 2006;295:1252.
-
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Lancet. 2005;365:1389-1397. Erratum in: Lancet. 2005;366:370.
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
Grundy SM, Cleeman JI, Merz CN, et al.; Coordinating Committee of the National Cholesterol Education Program. Circulation. 2004;110:227-239. (Erratum in: Circulation. 2004;110:763.)
-
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. N Engl J Med. 2003;348:383-393.
